ATG31 Antibody

What is ATG31 and why is it important in autophagy research?

ATG31 is an essential component of the Atg17-Atg31-Atg29 complex that plays a crucial role in the early stages of autophagy. This protein complex functions as a scaffold for pre-autophagosomal structure (PAS) organization and recruits other autophagy-related proteins to the PAS . The functional importance of ATG31 lies in its role in autophagy induction in response to various stimuli including nitrogen starvation, amino acid starvation, and rapamycin treatment . Research has demonstrated that deletion of the ATG31 gene significantly impairs autophagy, highlighting its essential nature in this cellular process. Understanding ATG31 function is fundamental for researchers investigating autophagy mechanisms, particularly in yeast models where the protein was first characterized.

When selecting antibodies for ATG31 research, it's important to understand that this protein undergoes post-translational modifications, primarily phosphorylation, which may affect antibody recognition depending on the epitope being targeted. Mass spectrometry analysis has identified multiple phosphorylation sites on ATG31, with serine 174 (S174) being particularly significant for autophagy function . This knowledge should inform your choice of antibody based on your specific research questions about ATG31's role in autophagy regulation.

How should ATG31 antibodies be validated for research use?

Proper validation of ATG31 antibodies requires multiple complementary approaches to ensure specificity and reliability. First, perform Western blotting using both wild-type cells and ATG31 knockout/deletion strains to confirm antibody specificity—true ATG31 antibodies will show bands at approximately 40-45 kDa in wild-type samples but not in deletion mutants . Be aware that ATG31 migrates abnormally on SDS-PAGE, appearing at approximately 40-45 kDa despite its calculated molecular weight of only 22 kDa due to its intrinsically disordered regions .

For phospho-specific antibodies targeting sites like S174, validation should include treatment with λ phosphatase to demonstrate that the signal disappears after dephosphorylation . Additionally, testing the antibody against phospho-mimetic mutants (e.g., S174D) and phospho-deficient mutants (e.g., S174A) can provide further confirmation of specificity . Immunofluorescence microscopy validation should demonstrate the expected localization pattern of ATG31 at the PAS, with additional controls showing altered localization under autophagy-inducing conditions like nitrogen starvation. Cross-reactivity testing against related ATG proteins is also essential to ensure the antibody doesn't recognize other components of the Atg17-Atg31-Atg29 complex.

What are the optimal conditions for detecting ATG31 using immunoblotting techniques?

For optimal detection of ATG31 in immunoblotting applications, researchers should be aware of several critical methodological considerations. Standard SDS-PAGE may not be sufficient for resolving ATG31 phosphorylation states. Consider using Phos-tag acrylamide gels (containing 25 mmol/L phos-tag acrylamide and 50 mmol/L MnCl₂) to enhance the separation of phosphorylated forms of ATG31 . Run these gels with a current of 15-20 mA for approximately 2 hours, followed by washing the gel with transfer buffer containing 1 mmol/L EDTA to remove Mn²⁺ before protein transfer to PVDF membranes .

When preparing samples, use lysis buffers containing phosphatase inhibitors to preserve the phosphorylation state of ATG31, particularly if you're investigating the S174 phosphorylation site. Cell lysis should be performed using methods gentle enough to preserve protein modifications but thorough enough for complete extraction—glass bead disruption in yeast has been successfully employed . For blocking, a 5% BSA solution in TBS-T is typically more effective than milk-based blocking buffers when working with phospho-specific antibodies. Primary antibody incubation should be optimized based on the specific antibody used, but overnight incubation at 4°C often yields the best results with reduced background. Additionally, when comparing ATG31 across different experimental conditions, be aware that the phosphorylation state remains relatively constant between starved and non-starved conditions unlike other autophagy proteins such as Atg13 .

How can researchers distinguish between differently phosphorylated forms of ATG31?

Distinguishing between the multiple phosphorylated forms of ATG31 requires sophisticated methodological approaches beyond standard immunoblotting. A robust approach combines Phos-tag SDS-PAGE with mass spectrometry validation. Prepare your Phos-tag gels with 25 mmol/L phos-tag acrylamide and 50 mmol/L MnCl₂ to achieve maximum separation of phosphorylated species . This technique enhances the mobility shifts of phosphorylated proteins, allowing visualization of different phospho-forms that would be indistinguishable on standard SDS-PAGE. For optimal results, run gels at 15-20 mA for approximately 2 hours, and transfer to PVDF membranes only after thoroughly washing the gel with 1 mmol/L EDTA to remove Mn²⁺ .

For definitive identification of specific phosphorylation sites, purify ATG31 using GST-tagged constructs expressed in yeast under both nutrient-rich and starvation conditions . The purified protein can then be analyzed using LC-MS/MS with a Thermo LTQ-Orbitrap Velos pro mass spectrometer or equivalent instrumentation. Configure your system for a 90-minute gradient elution at 0.250 μL/min flow rate, using a C-18 resin column (300 A, 5 μm) with mobile phase A (0.1% formic acid) and mobile phase B (80% acetonitrile and 0.1% formic acid) . When analyzing MS data, use high confidence score filters (FDR < 1%) and manually inspect MS/MS spectra to confirm phosphorylation sites. This combined approach has successfully identified all 11 phosphorylation sites on ATG31, with particular emphasis on the functionally critical S174 residue . For researchers specifically interested in S174 phosphorylation, developing phospho-specific antibodies remains challenging but would be valuable for monitoring this key regulatory site.

What are the best approaches for using ATG31 antibodies in studying alternative autophagy pathways?

When investigating alternative autophagy pathways alongside conventional mechanisms, researchers need sophisticated strategies for ATG31 antibody applications. The discovery that proteins like TRIM31 can promote autophagy independent of canonical factors like Atg5 and Atg7 has opened new research avenues . For these studies, implement a comparative immunoprecipitation approach using ATG31 antibodies in both wild-type cells and cells deficient in canonical autophagy components (Atg5-/-, Atg7-/-, Beclin1-knocked down, or LC3-knocked down cells) . This approach allows you to identify ATG31 interaction partners that function in alternative pathways.

For co-localization studies, combine ATG31 antibody staining with markers of alternative autophagy such as TRIM31, followed by super-resolution microscopy to precisely visualize spatial relationships . When designing these experiments, consider that alternative autophagy may be induced by specific stimuli—for example, lipopolysaccharide (LPS) strongly induces TRIM31-mediated alternative autophagy . Therefore, compare ATG31 localization and interactions under both baseline and stimulated conditions. For biochemical analysis of membrane associations, use subcellular fractionation techniques to isolate membrane compartments, followed by immunoblotting for ATG31 and alternative autophagy markers. This is particularly important since TRIM31-mediated alternative autophagy involves direct PE binding, which may influence ATG31 complex formation . Additionally, when using ATG31 antibodies in cells with active alternative autophagy pathways, be aware that rapid protein degradation may occur through both autophagy and proteasome-dependent mechanisms, potentially requiring proteasome inhibitors like MG132 to stabilize protein levels for detection .

How can researchers overcome challenges in detecting phosphorylated S174 of ATG31?

Detecting the phosphorylated S174 residue of ATG31 presents significant challenges, as noted by researchers who have attempted and failed to generate specific antibodies against this phosphorylation site . To overcome this obstacle, implement a multi-faceted approach combining genetic, biochemical, and imaging techniques. Begin by generating yeast strains expressing phosphomimetic (S174D) and phosphodeficient (S174A) ATG31 mutants as positive and negative controls for validating any potential phospho-specific antibodies . For antibody development, consider using multiple phosphopeptide immunogens with different carrier proteins and varying the lengths of the peptide sequence surrounding S174.

If direct detection remains problematic, employ proxy measurements of S174 phosphorylation status. For instance, monitor Atg9 recycling from the PAS, which is impaired in the S174A mutant, resulting in Atg9 puncta accumulation . Similarly, assess autophagosome formation using GFP-Atg8 translocation assays, as this process is also dependent on proper S174 phosphorylation . For structural analysis, combine your experimental approaches with computational modeling of ATG31 phosphorylation using tools like IUPred for disorder prediction and homologous modeling methods to understand how S174 phosphorylation affects the Atg17-Atg31-Atg29 complex interface .

When working with intrinsically disordered proteins like ATG31, standard antibody development approaches may fail due to conformational flexibility. In such cases, consider developing proximity ligation assays that can detect specific protein-protein interactions that depend on S174 phosphorylation, such as the interaction between ATG31 and ATG17 at their interface where S174 is located . This approach would provide an indirect but specific measure of S174 phosphorylation status in situ.

What experimental designs are optimal for studying ATG31 under different autophagy-inducing conditions?

When designing experiments to investigate ATG31 under various autophagy-inducing conditions, researchers should develop comprehensive protocols that account for the protein's constitutive phosphorylation and its role in different autophagy pathways. Set up parallel cultures of your model organism (typically yeast for ATG31 studies) and subject them to distinct autophagy-inducing treatments: nitrogen starvation (SD-N medium), amino acid starvation, and rapamycin treatment (typically 0.2 μg/mL) . For each condition, collect samples at multiple time points (0, 1, 2, and 4 hours) to capture the dynamics of ATG31 complex formation and function.

For microscopy-based experiments, transform cells with GFP-Atg8 as an autophagosome marker alongside your ATG31 constructs (wild-type or mutants) . Prepare cells for fluorescence microscopy by growing them to OD₆₀₀ = 0.8-1.0 in selective medium before shifting to treatment conditions . Image cells using confocal microscopy and quantify the percentage of cells with vacuolar GFP-Atg8 signals by counting at least 100 cells in three separate experiments . This approach allows direct comparison of autophagy efficiency across different conditions and genetic backgrounds. For biochemical analyses, perform subcellular fractionation to separate cytosolic and membrane-associated ATG31. This is particularly important because ATG31's function depends on its localization to the PAS. When analyzing ATG31 by immunoblotting, always include controls for total protein levels and use Phos-tag gels to monitor phosphorylation status . Additionally, compare results between wild-type ATG31 and the S174A mutant to assess the functional importance of phosphorylation under each autophagy-inducing condition .

What techniques can be used to study the role of ATG31 in Atg9 vesicle cycling using specific antibodies?

Investigating ATG31's role in Atg9 vesicle cycling requires sophisticated techniques leveraging both ATG31 and Atg9 antibodies. Design a comprehensive immunofluorescence microscopy protocol using antibodies against both proteins to visualize their spatial relationship in real-time. Fix cells using 4% paraformaldehyde after various autophagy-inducing treatments, and perform co-labeling with antibodies against ATG31 and Atg9. Use super-resolution microscopy (such as structured illumination or STORM) to achieve the resolution necessary for visualizing distinct vesicular structures and their dynamics. Quantify colocalization using appropriate software and statistical analysis, comparing wild-type cells with S174A mutants, which are known to accumulate Atg9-positive vesicles at the PAS .

For biochemical analysis of ATG31-Atg9 interactions, perform co-immunoprecipitation experiments using ATG31 antibodies, followed by immunoblotting for Atg9. This approach can reveal whether the interaction is direct or indirect and how it changes under different autophagy-inducing conditions. To specifically investigate Atg9 recycling, which is impaired in the S174A mutant, implement pulse-chase experiments using photoactivatable-GFP-tagged Atg9 . This technique allows tracking of Atg9 vesicle movement from the PAS. Additionally, perform subcellular fractionation to isolate different membrane compartments, followed by immunoblotting for both ATG31 and Atg9 to determine their distribution patterns. For a comprehensive understanding, combine these approaches with electron microscopy using immunogold labeling of both ATG31 and Atg9. This allows direct visualization of their localization at the ultrastructural level, particularly at the PAS where Atg9 vesicles accumulate in S174A mutants . Through these combined approaches, researchers can elucidate how ATG31 phosphorylation regulates Atg9 vesicle cycling during autophagosome formation.

How can ATG31 antibodies be used in comparative studies of conventional versus alternative autophagy pathways?

Designing comparative studies of conventional versus alternative autophagy pathways using ATG31 antibodies requires careful experimental planning. Begin by establishing cellular models representing both pathways: wild-type cells for conventional autophagy and cells deficient in core components (Atg5-/-, Atg7-/-) for alternative autophagy . For these experiments, use both yeast models (focusing on ATG31) and mammalian cell lines (examining both ATG31 homologs and alternative pathway proteins like TRIM31). Implement immunoblotting protocols that can detect ATG31 in parallel with canonical autophagy markers (LC3, Atg8) and alternative autophagy markers (TRIM31) . For optimal comparison, stimulate both pathways using appropriate inducers—nitrogen starvation for conventional autophagy and LPS treatment for TRIM31-mediated alternative autophagy .

For high-resolution visualization, perform multi-color immunofluorescence microscopy using antibodies against ATG31, conventional autophagy markers, and alternative autophagy markers. This approach allows assessment of colocalization patterns under different stimulation conditions. Quantify the degree of overlap using Pearson's correlation coefficient or Mander's overlap coefficient across multiple cells and experimental conditions. To investigate the functional relationships between conventional and alternative pathways, conduct proximity ligation assays (PLA) using antibody pairs targeting ATG31 and components of either pathway. This technique reveals direct protein-protein interactions occurring within 40 nm distance, providing insight into whether ATG31 participates in both pathways or primarily functions in conventional autophagy. Additionally, to assess the significance of ATG31 in each pathway, perform ATG31 immunoprecipitation followed by mass spectrometry to identify interacting partners under different autophagy-inducing conditions. This approach can reveal whether ATG31 forms distinct protein complexes during conventional versus alternative autophagy . The comparative approach is particularly valuable when studying bacterial infection models, where both pathways may contribute to pathogen clearance through different mechanisms .

How should researchers address non-specific binding or weak signals when using ATG31 antibodies?

When encountering non-specific binding or weak signals with ATG31 antibodies, implement a systematic troubleshooting approach addressing both experimental conditions and antibody quality. First, optimize blocking conditions by testing alternative blocking reagents—5% BSA in TBS-T is often superior to milk-based blockers, especially for phospho-specific applications. Extend blocking time to 2 hours at room temperature to minimize non-specific binding. For persistent background issues, try adding 0.1-0.5% Triton X-100 to wash buffers and increasing both the number and duration of washing steps. If weak signals are the primary concern, consider signal amplification techniques such as biotin-streptavidin systems or tyramide signal amplification for immunofluorescence applications.

Be aware that ATG31's unique structural properties, particularly its intrinsically disordered regions, may affect epitope accessibility and antibody binding . To address this, test alternative sample preparation methods—for immunoblotting, try different detergents in lysis buffers or vary denaturation conditions; for immunofluorescence, compare different fixation protocols (paraformaldehyde, methanol, or combination methods). Additionally, implement antigen retrieval techniques like heat-induced epitope retrieval or enzymatic treatment for improved epitope accessibility in fixed samples. If non-specific bands persist in immunoblotting, use ATG31 knockout/deletion samples as negative controls to definitively identify non-specific signals . For weak signals in yeast studies, consider using overexpression systems with epitope tags (such as GST-ATG31) to enhance detection sensitivity . Also, validate antibody performance across different experimental conditions (nutrient-rich versus starvation), as ATG31's localization and complex formation may change, potentially affecting antibody accessibility to epitopes.

What are the critical considerations when using ATG31 antibodies in different model organisms?

When applying ATG31 antibodies across different model organisms, researchers must address several critical considerations related to evolutionary conservation, expression patterns, and technical compatibility. First, perform sequence alignment analysis to assess the conservation of ATG31 epitopes between species—while the functional domains of autophagy proteins are generally conserved, epitope sequences recognized by antibodies may vary significantly. For example, while yeast Saccharomyces cerevisiae ATG31 shares structural similarities with Lachancea thermotolerans ATG31, specific amino acid differences may affect antibody recognition . Test antibody cross-reactivity empirically by performing side-by-side Western blots with protein extracts from different species under identical conditions.

For mammalian studies, be aware that ATG31 homologs may have different nomenclature or may function within different protein complexes compared to yeast. Validate antibody specificity in each model organism using genetic knockouts or RNAi-mediated knockdowns as negative controls. Consider that post-translational modifications, particularly phosphorylation patterns like those at S174 in yeast, may differ between species, affecting epitope recognition . For immunohistochemistry or tissue-specific studies, optimize fixation and permeabilization protocols for each tissue type, as cellular composition can significantly impact antibody accessibility. In organisms with tissue-specific expression patterns, verify ATG31 expression in your tissue of interest before conducting extensive antibody-based experiments. Additionally, when studying ATG31 in the context of alternative autophagy, remember that pathway components like TRIM31 show species-specific and tissue-specific expression patterns—for example, TRIM31 is intestine-specific in humans . Finally, for developmental studies, confirm that ATG31 expression timing matches your experimental window, as autophagy protein expression can vary dramatically during development.

How can researchers integrate ATG31 antibody-based techniques with other methodologies to address contradictory data?

When confronted with contradictory data regarding ATG31 function or localization, researchers should implement an integrated multi-methodological approach to resolve discrepancies. Begin by comparing results from different antibody-based techniques—if immunofluorescence results conflict with immunoblotting data, the discrepancy may stem from differences in protein conformation or epitope accessibility between methods. Validate antibody specificity using multiple negative controls including genetic knockouts and peptide competition assays. For phosphorylation-specific contradictions, employ both Phos-tag gel electrophoresis and lambda phosphatase treatment to definitively establish phosphorylation status .

To resolve spatial localization contradictions, implement live-cell imaging with fluorescently-tagged ATG31 constructs alongside fixed-cell immunofluorescence. This combination can reveal whether fixation artifacts are contributing to contradictory results. When conflicting data emerges regarding ATG31's role in conventional versus alternative autophagy pathways, design experiments in genetic knockout systems (Atg5-/-, Atg7-/-, Beclin1 knockdown) to isolate pathway-specific functions . For contradictory protein-protein interaction data, complement antibody-based co-immunoprecipitation with proximity ligation assays and FRET/BRET approaches to assess interactions with spatial resolution in intact cells.

For functional contradictions regarding ATG31's role in autophagy, combine antibody-based techniques with functional readouts like autophagy flux assays (using GFP-Atg8 processing), electron microscopy for ultrastructural analysis, and autophagic cargo degradation assays . Additionally, employ computational modeling of the ATG31 structure, particularly focusing on how phosphorylation affects its interaction with complex partners like ATG17 . This integrated approach can help determine whether contradictions arise from technical limitations, biological complexity, or context-dependent functions of ATG31 in different autophagy pathways. Remember that ATG31 has intrinsically disordered regions, which may result in context-dependent structural conformations that could explain seemingly contradictory experimental results .

How can ATG31 antibodies be applied in studying the relationship between conventional autophagy and bacterial clearance?

Investigating the relationship between conventional autophagy and bacterial clearance using ATG31 antibodies requires sophisticated experimental designs that capture the dynamic interplay between host defense mechanisms and pathogen interactions. Establish infection models using bacteria like Shigella, which are known targets of both conventional and alternative autophagy pathways . Design time-course experiments collecting samples at multiple points post-infection (30 minutes, 1, 2, 4, and 8 hours) to capture the dynamic response of ATG31-mediated processes. Implement immunofluorescence protocols combining antibodies against ATG31, bacterial markers, and autophagy proteins (both conventional and alternative) to visualize the recruitment of autophagy machinery to bacterial entry sites.

For quantitative assessment of bacteria clearance efficiency, compare wild-type cells with those expressing ATG31 mutants (particularly S174A) to determine how phosphorylation affects bacterial targeting . Additionally, examine cells with knockouts of canonical autophagy components (Atg5, Atg7) but expressing functional ATG31 to isolate its contribution to alternative autophagy-mediated bacterial clearance . For biochemical analysis, perform subcellular fractionation to isolate bacteria-containing vesicles, followed by immunoblotting for ATG31 and other autophagy markers. This approach can reveal whether ATG31 is recruited to bacteria-containing compartments independently of the complete Atg17-Atg31-Atg29 complex. Combine these approaches with bacterial survival assays to correlate ATG31 recruitment with functional bacterial clearance outcomes. Through this integrated approach, researchers can elucidate whether ATG31 contributes to bacterial defense through conventional autophagy mechanisms, alternative pathways, or both simultaneously, providing insight into the protein's potentially multifaceted role in antimicrobial defense.

What innovative microscopy techniques can enhance ATG31 antibody-based visualization of autophagy dynamics?

Advanced microscopy techniques can dramatically enhance our understanding of ATG31 dynamics during autophagy when combined with optimized antibody applications. Implement super-resolution microscopy approaches such as Structured Illumination Microscopy (SIM), Stimulated Emission Depletion (STED), or Single-Molecule Localization Microscopy (STORM/PALM) to visualize ATG31 localization with nanometer precision. These techniques can resolve the spatial relationship between ATG31 and other components of the autophagy machinery at the PAS, which is not possible with conventional confocal microscopy. For temporal dynamics, combine fixed-time immunofluorescence with live-cell imaging using complementary approaches like split-fluorescent protein systems, where one fragment is fused to ATG31 and the other to interaction partners.

Develop correlative light and electron microscopy (CLEM) protocols using ATG31 antibodies for immunogold labeling, allowing precise localization of ATG31 in relation to ultrastructural features of autophagosomes. This is particularly valuable for understanding how ATG31 contributes to membrane remodeling during autophagosome formation. For multiplexed analysis, implement cycling immunofluorescence or mass cytometry imaging, allowing simultaneous visualization of ATG31 alongside numerous other autophagy factors and post-translational modifications. These approaches can reveal how ATG31 functions within the broader autophagy interaction network.

For studying ATG31 in the context of its intrinsically disordered regions, consider Förster Resonance Energy Transfer (FRET)-based approaches combined with antibodies against specific conformational states. This can provide insight into how structural changes in ATG31, particularly those induced by phosphorylation at S174, affect its interaction with partners in the Atg17-Atg31-Atg29 complex . Additionally, implement lattice light-sheet microscopy for long-term imaging with minimal phototoxicity, allowing visualization of ATG31 dynamics throughout the entire autophagy process from initiation to autophagosome completion, providing unprecedented insights into the temporal aspects of ATG31 function.